Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.

doi:10.1038/s41591-020-0762-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.

Nature medicine - 1 Mar 2020

Thijssen Elisabeth H, La Joie Renaud, Wolf Amy, Strom Amelia, Wang Ping, Iaccarino Leonardo, Bourakova Viktoriya, Cobigo Yann, Heuer Hilary, Spina Salvatore, VandeVrede Lawren, Chai Xiyun, Proctor Nicholas K, Airey David C, Shcherbinin Sergey, Duggan Evans Cynthia, Sims John R, Zetterberg Henrik, Blennow Kaj, Karydas Anna M, Teunissen Charlotte E, Kramer Joel H, Grinberg Lea T, Seeley William W, Rosen Howie, Boeve Bradley F, Miller Bruce L, Rabinovici Gil D, Dage Jeffrey L, Rojas Julio C, Boxer Adam L

Abstract excerpt

With the potential development of new disease-modifying Alzheimer's disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amyloid beta-Peptides

Share to Cognition

Share to Frontotemporal Lobar Degeneration

Share to Gray Matter

Share to Neurofilament Proteins

Share to Positron-Emission Tomography

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 32123386
DOI: 10.1038/s41591-020-0762-2
PMCID: PMC7101073

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.PMID 32123386Read ↗

Plasma pTau181 as a biomarker for Alzheimer's diseaseSemantic proximity Read ↗

Clinical and demographic factors modify the association between plasma phosphorylated tau-181 and cognitionSemantic proximity Read ↗

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort studySemantic proximity Read ↗

A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsSemantic proximity Read ↗

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.Semantic proximity Read ↗

Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.Semantic proximity Read ↗

Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesSemantic proximity Read ↗

Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real‐world population‐based cohortSemantic proximity Read ↗

Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsSemantic proximity Read ↗

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declinesSemantic proximity Read ↗

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity Read ↗

Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.